- Home
- KMDA vs IMAB Comparison
KMDA vs IMAB Comparison
Compare KMDA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- IMAB
- Stock Information
- Founded
- KMDA 1990
- IMAB 2014
- Country
- KMDA Israel
- IMAB United States
- Employees
- KMDA N/A
- IMAB N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KMDA Health Care
- IMAB Health Care
- Exchange
- KMDA Nasdaq
- IMAB Nasdaq
- Market Cap
- KMDA 410.6M
- IMAB 384.6M
- IPO Year
- KMDA N/A
- IMAB 2020
- Fundamental
- Price
- KMDA $6.95
- IMAB $3.65
- Analyst Decision
- KMDA Strong Buy
- IMAB Strong Buy
- Analyst Count
- KMDA 2
- IMAB 5
- Target Price
- KMDA $13.00
- IMAB $6.80
- AVG Volume (30 Days)
- KMDA 50.0K
- IMAB 1.7M
- Earning Date
- KMDA 11-12-2025
- IMAB 11-02-2025
- Dividend Yield
- KMDA 2.90%
- IMAB N/A
- EPS Growth
- KMDA 27.97
- IMAB N/A
- EPS
- KMDA 0.32
- IMAB N/A
- Revenue
- KMDA $169,517,000.00
- IMAB N/A
- Revenue This Year
- KMDA $14.49
- IMAB N/A
- Revenue Next Year
- KMDA $10.12
- IMAB N/A
- P/E Ratio
- KMDA $20.92
- IMAB N/A
- Revenue Growth
- KMDA 9.67
- IMAB N/A
- 52 Week Low
- KMDA $5.17
- IMAB $0.60
- 52 Week High
- KMDA $9.16
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- KMDA 44.35
- IMAB 44.73
- Support Level
- KMDA $6.84
- IMAB $3.20
- Resistance Level
- KMDA $7.15
- IMAB $4.64
- Average True Range (ATR)
- KMDA 0.19
- IMAB 0.38
- MACD
- KMDA -0.00
- IMAB -0.16
- Stochastic Oscillator
- KMDA 23.02
- IMAB 29.87
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).